FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2582170064> ?p ?o ?g. }

• W2582170064 endingPage "17832" @default.
• W2582170064 startingPage "17819" @default.
• W2582170064 abstract "// Carmela Ricciardelli 1 , Noor A. Lokman 1 , Carmen E. Pyragius 1 , Miranda P. Ween 2 , Anne M. Macpherson 1 , Andrew Ruszkiewicz 3 , Peter Hoffmann 4 , Martin K. Oehler 1, 5 1 Discipline of Obstetrics and Gynaecology, School of Medicine, Robinson Research Institute, University of Adelaide, Adelaide, 5000, South Australia, Australia 2 Lung Research Laboratory, Hanson Institute, Adelaide, South Australia, Australia, Department of Thoracic Medicine, Royal Adelaide Hospital, Adelaide, 5000, South Australia, Australia 3 Centre of Cancer Biology, University of South Australia and Department of Anatomical Pathology, SA Pathology, Adelaide, 5000, South Australia, Australia 4 Adelaide Proteomics Centre, School of Biological Sciences, University of Adelaide, Adelaide, 5005, South Australia, Australia 5 Department of Gynaecological Oncology, Royal Adelaide Hospital, Adelaide, 5000, South Australia, Australia Correspondence to: Carmela Ricciardelli, email: carmela.ricciardelli@adelaide.edu.au Keywords: ovarian cancer, keratin 5, tumor progression, recurrence, chemoresistance Received: October 01, 2015      Accepted: January 16, 2017      Published: January 27, 2017 ABSTRACT This study investigated the clinical significance of keratin 5 and 6 expression in serous ovarian cancer progression and chemotherapy resistance. KRT5 and KRT6 ( KRT6A , KRT6B & KRT6C ) gene expression was assessed in publically available serous ovarian cancer data sets, ovarian cancer cell lines and primary serous ovarian cancer cells. Monoclonal antibodies which detect both K5/6 or only K5 were used to assess protein expression in ovarian cancer cell lines and a cohort of high grade serous ovarian carcinomas at surgery ( n = 117) and after neoadjuvant chemotherapy ( n = 21). Survival analyses showed that high KRT5 mRNA in stage III/IV serous ovarian cancers was significantly associated with reduced progression-free (HR 1.38, P < 0.0001) and overall survival (HR 1.28, P = 0.013) whilst high KRT6 mRNA was only associated with reduced progression-free survival (HR 1.2, P = 0.031). Both high K5/6 (≥ 10%, HR 1.78 95% CI; 1.03−2.65, P = 0.017) and high K5 (≥ 10%, HR 1.90, 95% CI; 1.12−3.19, P = 0.017) were associated with an increased risk of disease recurrence. KRT5 but not KRT6C mRNA expression was increased in chemotherapy resistant primary serous ovarian cancer cells compared to chemotherapy sensitive cells. The proportion of serous ovarian carcinomas with high K5/6 or high K5 immunostaining was significantly increased following neoadjuvant chemotherapy. K5 can be used to predict serous ovarian cancer prognosis and identify cancer cells that are resistant to chemotherapy. Developing strategies to target K5 may therefore improve serous ovarian cancer survival." @default.
• W2582170064 created "2017-02-03" @default.
• W2582170064 creator A5003053999 @default.
• W2582170064 creator A5021577277 @default.
• W2582170064 creator A5023598832 @default.
• W2582170064 creator A5042201449 @default.
• W2582170064 creator A5048188053 @default.
• W2582170064 creator A5060655524 @default.
• W2582170064 creator A5075987104 @default.
• W2582170064 creator A5087706210 @default.
• W2582170064 date "2017-01-27" @default.
• W2582170064 modified "2023-10-11" @default.
• W2582170064 title "Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance" @default.
• W2582170064 cites W1495654654 @default.
• W2582170064 cites W1520417253 @default.
• W2582170064 cites W179078680 @default.
• W2582170064 cites W1851162873 @default.
• W2582170064 cites W1921543583 @default.
• W2582170064 cites W1968261842 @default.
• W2582170064 cites W1982406735 @default.
• W2582170064 cites W1984102131 @default.
• W2582170064 cites W1985801265 @default.
• W2582170064 cites W1987092017 @default.
• W2582170064 cites W1991527725 @default.
• W2582170064 cites W1992146811 @default.
• W2582170064 cites W1994686262 @default.
• W2582170064 cites W1999139669 @default.
• W2582170064 cites W2000357107 @default.
• W2582170064 cites W2001962377 @default.
• W2582170064 cites W2002484499 @default.
• W2582170064 cites W2004684462 @default.
• W2582170064 cites W2008510706 @default.
• W2582170064 cites W2011633494 @default.
• W2582170064 cites W2014476767 @default.
• W2582170064 cites W2016693266 @default.
• W2582170064 cites W2021049263 @default.
• W2582170064 cites W2022026778 @default.
• W2582170064 cites W2027566169 @default.
• W2582170064 cites W2038935831 @default.
• W2582170064 cites W2040087423 @default.
• W2582170064 cites W2044702943 @default.
• W2582170064 cites W2045376146 @default.
• W2582170064 cites W2046741252 @default.
• W2582170064 cites W2048672627 @default.
• W2582170064 cites W2051215463 @default.
• W2582170064 cites W2055774906 @default.
• W2582170064 cites W2057275128 @default.
• W2582170064 cites W2060465115 @default.
• W2582170064 cites W2064084120 @default.
• W2582170064 cites W2064651874 @default.
• W2582170064 cites W2068108952 @default.
• W2582170064 cites W2068854353 @default.
• W2582170064 cites W2078849660 @default.
• W2582170064 cites W2081162371 @default.
• W2582170064 cites W2085029669 @default.
• W2582170064 cites W2088153204 @default.
• W2582170064 cites W2094833794 @default.
• W2582170064 cites W2097255042 @default.
• W2582170064 cites W2097554174 @default.
• W2582170064 cites W2099335989 @default.
• W2582170064 cites W2101689123 @default.
• W2582170064 cites W2101692676 @default.
• W2582170064 cites W2104028450 @default.
• W2582170064 cites W2104858899 @default.
• W2582170064 cites W2106999675 @default.
• W2582170064 cites W2109221809 @default.
• W2582170064 cites W2111440805 @default.
• W2582170064 cites W2113123304 @default.
• W2582170064 cites W2114843025 @default.
• W2582170064 cites W2124098247 @default.
• W2582170064 cites W2137162822 @default.
• W2582170064 cites W2143017330 @default.
• W2582170064 cites W2146968962 @default.
• W2582170064 cites W2149441684 @default.
• W2582170064 cites W2161024553 @default.
• W2582170064 cites W2164692369 @default.
• W2582170064 cites W2259802687 @default.
• W2582170064 cites W2408710509 @default.
• W2582170064 cites W2532129465 @default.
• W2582170064 cites W2917837889 @default.
• W2582170064 cites W752689871 @default.
• W2582170064 doi "https://doi.org/10.18632/oncotarget.14867" @default.
• W2582170064 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5392289" @default.
• W2582170064 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28147318" @default.
• W2582170064 hasPublicationYear "2017" @default.
• W2582170064 type Work @default.
• W2582170064 sameAs 2582170064 @default.
• W2582170064 citedByCount "40" @default.
• W2582170064 countsByYear W25821700642017 @default.
• W2582170064 countsByYear W25821700642018 @default.
• W2582170064 countsByYear W25821700642019 @default.
• W2582170064 countsByYear W25821700642020 @default.
• W2582170064 countsByYear W25821700642021 @default.
• W2582170064 countsByYear W25821700642022 @default.
• W2582170064 countsByYear W25821700642023 @default.
• W2582170064 crossrefType "journal-article" @default.
• W2582170064 hasAuthorship W2582170064A5003053999 @default.
• W2582170064 hasAuthorship W2582170064A5021577277 @default.

• next